Pharma firms likely to post 11% growth in sales, EBITDA in Q1FY26: Report
However, the report added that the muted domestic demand in April and March may slightly offset gains.
The hospitals segment is projected to see robust 17 per cent year-on-year growth in both sales and EBITDA, supported by increased footfalls, new bed additions, and a modest rise in ARPOB.
In diagnostics, volume growth, better mix, and M&A activity are expected to contribute to a 14 per cent YoY sales increase across the coverage.
"For pharma companies, we expect continued traction across most markets to drive 11%/11% yoy growth in overall sales/EBITDA in 1QFY26," the report added.
India's pharmaceutical market for FY 2023-24 is valued at USD 50 billion with domestic consumption valued at USD 23.5 billion and export valued at USD 26.5 billion.
The domestic pharma industry is considered to be the world's third largest by volume and 14th in terms of value of production. With an extremely diversified product base covering generic drugs, bulk drugs, over-the-counter drugs, vaccines, biosimilars, and biologics, the Indian pharmaceutical industry has a strong presence at the global level.
According to National Accounts Statistics 2024, published by the Ministry of Statistics and Programme Implementation, total output for industry i.e. Pharmaceuticals, medicinal and botanical products is Rs. 4,56,246 crores for FY 2022-23 at constant prices, of which value added is ₹ 1,75,583 crores.
As per government data 9,25,811 number of persons are engaged in Pharmaceuticals, medicinal and botanical products industry during FY 2022-23.
Research & Development (R&D) and innovation in Pharma Sector is done by number of institutions and organizations under various scientific Ministries/Departments.
The Department of Pharmaceuticals has set up seven National Institutes of Pharmaceutical Education & Research (NIPERs) as institutes of national importance, which besides imparting postgraduate and doctorate education, conduct high end research in various pharma specializations.
Further, Department has framed a "National Policy on Research & Development and Innovation in Pharma-MedTech Sector in India" to encourage R&D in pharmaceuticals and medical devices.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
14 minutes ago
- The Hindu
‘Infosys doesn't want employees to work extra hours to ensure work-life balance, better productivity'
At a time when N. R. Narayanamurthy is holding firm about Indian workers logging in at least 70-hour work weeks, the company he co-founded and has later retired from, Infosys, has been mailing its employees to ensure they maintain a good work-life balance. The country's second-largest tech firm wants its employees to work only 9.15 hours, five days a week, on average. And, if anyone is found working more hours than required, a system triggers a message to that employee reminding him or her of the importance of work-life balance. This platform tracks all employees working from home and from various offices of the company. 'We reach out to employees who are spending more time at work very proactively to ensure proper work-life balance and encourage them to focus on holistic well-being,' said a source at the company. Infosys is currently in a silent period and therefore did not comment officially. 'Our commitment to mental and physical wellness is supported by a wide range of health initiatives and resources. Through our award-winning HALE (Health Assessment and Lifestyle Enrichment) programme, we continue to foster a culture of health, safety, and overall wellness,' he further said. According to information available with The Hindu, since its inception, HALE has done pioneering work in the area of employee health (physical & mental), employee safety, encouraging leisure and creating and sustaining a healthy workforce, which can balance work life and is productive. HALE has four key pillars to make the programme more holistic: Health, Safety, Leisure and Emotional Wellbeing. 'A proactive approach to health and life enrichment aimed at increased awareness, overall wellbeing resulting in good health, reduced stress levels, safe work environment and improved productivity levels,' says the company. The source further said, the Infosys Employee Relations team anchored activities which involve constant employee engagement and understanding of people issues. Through their experience, the team found strong evidence of an early onset of physical, mental and psycho-somatic illness in a young workforce. A sedentary lifestyle coupled with high work pressure and stress was resulting in heart ailments, high blood pressure, cases of depression and mental disorders, cases of suicide, attempts at bodily harm, and many cases of marital discord. 'Yes, we have deadlines and a lot of stress at work. Still, we have facilities at the workplace to relax, rest and rejuvenate ourselves. These days, bosses don't want us to work extra hours and they want us to focus on work-life balance and be productive,'' said a techie employed by Infosys. Further, medical research corroborated these findings and showed that proactive early interventions that lead to early detection, coupled with treatment options and lifestyle changes, can contribute significantly towards enhancing the active working age of an individual as well as directly impact workplace productivity. A twin focus on the Infosys commitment to provide employees an emotional value proposition as well as on the company's adherence to its core values led to the formation of HALE, the source added.
News18
16 minutes ago
- News18
Stock Market Updates: GIFT Nifty Hints Muted Start; Trump Shifts Tariff Deadline To Aug 1
Last Updated: Indian stock markets are likely to open on a cautious note, with a flat-to-negative bias on Monday, July 7 Sensex Today: Indian stock markets are likely to open on a cautious note, with a flat-to-negative bias on Monday, July 7, as investors react to the latest updates on US tariff measures under President Donald Trump's administration. US Treasury Secretary Scott Bessent announced on Sunday that the new tariffs will be enforced starting August 1 for countries that fail to finalise trade agreements with the US — a list that currently includes India. Bessent stated that the extended timeline is meant to give US trading partners additional time to renegotiate tariff terms. The uncertainty around India's pending trade agreement with the US could weigh on investor sentiment. As of 6:40 AM, GIFT Nifty futures were trading 13 points lower at the 25,528 level, indicating a muted start for domestic indices. Apart from global cues, market focus will gradually shift toward the first quarter earnings season for FY26. Tata Consultancy Services (TCS) will kick off the results season with its Q1 numbers scheduled for July 10. Other key earnings include DMart on July 11, HCL Technologies on July 14, and Tech Mahindra on July 16. With no major domestic triggers expected today, the market is likely to remain stock-specific. Trends in foreign institutional investor (FII) flows and cues from global markets will play a critical role in driving sentiment through the session. Global Markets Update: Asian markets were mostly in the red on Monday, dragged lower by uncertainty over the shifting US tariff deadline. Japan's Nikkei 225 dipped 0.26%, while South Korea's Kospi shed 0.48%. Australia's S&P/ASX 200 hovered near the flat line in early trade. In the US, stock futures indicated a weak start for Wall Street. Dow Jones Industrial Average futures were down 146 points, or 0.32%. S&P 500 futures slipped 0.39%, and Nasdaq 100 futures declined 0.42%, reflecting cautious sentiment amid global trade concerns. About the Author Aparna Deb Stay updated with all the latest news on the Stock Market, including market trends, Sensex and Nifty updates, top gainers and losers, and expert analysis. Get real-time insights, financial reports, and investment strategies—only on News18. Location : New Delhi, India, India First Published: News business » markets Stock Market Updates: GIFT Nifty Hints Muted Start; Trump Shifts Tariff Deadline To Aug 1
Time of India
16 minutes ago
- Time of India
Top stocks to buy or sell today: Stock recommendations for July 7, 2025 - here's what brokerages are saying
Top stocks to buy or sell (AI image) Nuvama has downgraded its rating on Trent to hold from buy and cut its target price to Rs 5,884 from Rs 6,627. The analysts believe Trent Hypermarket (Star Bazaar) can become bigger than Westside and Zudio given the size of the food industry. Star Bazaar is focused on the company's branded products while Big Basket is relatively more expensive. There are no plans to merge these two businesses. Trent plans to add over 250 stores in all formats combined for FY26 and may add more depending on market conditions and availability of investable properties. However, current run rate falls short of management's aspiration of 25% growth over the next few years. Pickup in Zudio Beauty and the Star business can become the next big growth levers but these businesses need to stabilise before scaling up. Morgan Stanley maintained its underweight rating on Bank of Baroda with a target price of Rs 235. Analysts said that as expected in April-June quarter growth moderated. The lender's domestic loan growth moderated to 12.4% on an annual basis compared to 13.7% (below industry rate), while the domestic deposit growth moderated to 8.1% from 9.3% (also below industry rate). BoB's loan to deposit ratio of 82% is elevated and could weigh on loan growth if deposit growth stays muted. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 3.5, 4.5 BHK Homes starting at ₹4.89 Cr.* Hero Homes Learn More Undo Motilal Oswal Securities maintained its neutral rating on IndusInd Bank with the target price at Rs 800. Analysts feel operating performance will recover gradually and they estimate 1% return on assets by FY28. They also expect business growth to remain under pressure in near term, loan growth to remain modest, estimated at 7% on an annual basis during the current fiscal. Bank to retire high-cost liabilities and near-term growth is expected to remain muted. Nomura has a neutral rating on Bandhan Bank with the target price at Rs 165. Analysts said they expect the lender's April-June quarter to show weak loan growth with a sharp decline in CASA to 27.1%, a drop of 430 basis points. They also expect overall collection efficiency to decline by 20 basis points to 97.7%. Jefferies maintained its buy rating on Bajaj Finance with the target price at Rs 1,044. Analysts said they expect the NBFC major in April-June quarter would show a healthy growth despite softer market trends. And this growth is encouraging as it comes in a quarter when sales of consumer durables were down. The company's AUM growth may have been aided by better trends in other segments, including cross-sell of personal loans and SME loans. The NBFC major is also expected to show healthy asset growth, and its easing fund cost can aid earnings and valuations. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
